Hitoshi Setoyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hitoshi Setoyama has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Akio Ido
Kagoshima University Graduate School of Medical and Dental Sciences
10 shared publications - Hirohito Tsubouchi
Department of Digestive and Life-Style Related Disease, Health Research Course, Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima
9 shared publications - Masatsugu Numata
HGF Hepatic Regeneration Therapy Project, Department of Experimental Therapeutics, Translational Research Center, Kyoto University Hospital, Kyoto, Japan
7 shared publications - Akihiro Moriuchi
Digestive Disease and Life-style Related Disease, Kagoshima University Graduate School of Medical and Dental Sciences
6 shared publications Hiroshi Fujita
6 shared publications- Naohisa Yamaji
HGF Hepatic Regeneration Therapy Project, Department of Experimental Therapeutics, Translational Research Center, Kyoto University Hospital, Kyoto, Japan
5 shared publications
Latest Publications
- Open Access
- 4 April 2017
- Published by Springer Nature in Environmental Health and Preventive Medicine
- Vol. 22 (1) , 1-11
Potential predictors of susceptibility to occupational stress in Japanese novice nurses - a pilot study
Occupational stress is a known factor behind employee resignations; thus, early identification of individuals prone to such stress is important. Accordingly, in this pilot study we evaluated potential predictors of susceptibility to occupational stress in Japanese novice nurses. Forty-two female novice nurses at Kagoshima University Hospital were recruited for the study population. Each underwent physical health and urinary examinations, and completed a lifestyle questionnaire at the time of job entry. Each also completed a Brief Job Stress Questionnaire (BJSQ), related to mental health status, at job entry and 5 months post-entry. Psychological stress, somatic symptoms, and combined BJSQ scores were determined for each time point. All three stress condition scores had significantly decreased at 5 months post-entry, suggesting occupational stress. Systolic blood pressure (r = −0.324, p < 0.05) and urinary sodium (r = −0.313, p < 0.05) were significantly negatively correlated with combined BJSQ score at 5 months post-entry. Post-entry stress condition scores were significantly low in subjects reporting substantial 1-year body weight change (≤ ± 3 kg) and short times between dinner and bedtimes (≤2 h), though baseline stress condition scores were not. Urinary sodium concentration, 1-year body weight change, and pre-sleep evening meals were then targeted for multivariate analysis, and confirmed as independent explanatory variables for post-entry stress condition scores. One-year body weight change, times between dinner and bedtimes, and urinary sodium concentration are promising potential predictors of susceptibility to occupational stress, and should be further investigated in future research. ISRCTN ISRCTN17516023. Retrospectively registered 7 December 2016.
- 4 April 2017
- Published by Springer Nature in Environmental Health and Preventive Medicine
- Vol. 22 (1) , 1-11
Open AccessPotential predictors of susceptibility to occupational stress in Japanese novice nurses - a pilot study
Occupational stress is a known factor behind employee resignations; thus, early identification of individuals prone to such stress is important. Accordingly, in this pilot study we evaluated potential predictors of susceptibility to occupational stress in Japanese novice nurses. Forty-two female novice nurses at Kagoshima University Hospital were recruited for the study population. Each underwent physical health and urinary examinations, and completed a lifestyle questionnaire at the time of job entry. Each also completed a Brief Job Stress Questionnaire (BJSQ), related to mental health status, at job entry and 5 months post-entry. Psychological stress, somatic symptoms, and combined BJSQ scores were determined for each time point. All three stress condition scores had significantly decreased at 5 months post-entry, suggesting occupational stress. Systolic blood pressure (r = −0.324, p < 0.05) and urinary sodium (r = −0.313, p < 0.05) were significantly negatively correlated with combined BJSQ score at 5 months post-entry. Post-entry stress condition scores were significantly low in subjects reporting substantial 1-year body weight change (≤ ± 3 kg) and short times between dinner and bedtimes (≤2 h), though baseline stress condition scores were not. Urinary sodium concentration, 1-year body weight change, and pre-sleep evening meals were then targeted for multivariate analysis, and confirmed as independent explanatory variables for post-entry stress condition scores. One-year body weight change, times between dinner and bedtimes, and urinary sodium concentration are promising potential predictors of susceptibility to occupational stress, and should be further investigated in future research. ISRCTN ISRCTN17516023. Retrospectively registered 7 December 2016.
- 1 January 2016
- Published by Japan Pancreas Society in Suizo
- Vol. 31 (4) , 638-645
Successful visualization of the main pancreatic duct from the gastric fistula by narrow band imaging (NBI) magnification endoscopy in a patient with mixed type intraductal papillary mucinous carcinoma (IPMC)
症例は76歳女性.CTで主膵管の拡張と多房性の嚢胞性病変,総胆管の拡張を認めた.精査目的で紹介,混合型IPMNと診断された.主膵管から胃への穿破があったことから瘻孔より拡大内視鏡を挿入,粘液の除去とCO2送気下での観察を行った.NBI併用拡大観察にて膵管内の結節と絨毛状構造が明瞭となり,通常観察では一見正常に見えた膵管上皮においても絨毛状構造が描出されたことから病変の連続性を評価し得た.直視下にて結節部分より生検を行い,術前にIPMCと診断,膵全摘術を施行し,手術標本で膵管内進展を確認した.IPMN症例の内視鏡観察において腫瘍形態と血管像が良悪性度診断に重要とされている.今回,NBI併用拡大観察で主膵管内の腫瘍形態,血管像を詳細に観察し,膵管進展評価と術前病理診断ができたIPMCの一例を経験した.
- 1 January 2016
- Published by Japan Pancreas Society in Suizo
- Vol. 31 (4) , 638-645
Successful visualization of the main pancreatic duct from the gastric fistula by narrow band imaging (NBI) magnification endoscopy in a patient with mixed type intraductal papillary mucinous carcinoma (IPMC)
症例は76歳女性.CTで主膵管の拡張と多房性の嚢胞性病変,総胆管の拡張を認めた.精査目的で紹介,混合型IPMNと診断された.主膵管から胃への穿破があったことから瘻孔より拡大内視鏡を挿入,粘液の除去とCO2送気下での観察を行った.NBI併用拡大観察にて膵管内の結節と絨毛状構造が明瞭となり,通常観察では一見正常に見えた膵管上皮においても絨毛状構造が描出されたことから病変の連続性を評価し得た.直視下にて結節部分より生検を行い,術前にIPMCと診断,膵全摘術を施行し,手術標本で膵管内進展を確認した.IPMN症例の内視鏡観察において腫瘍形態と血管像が良悪性度診断に重要とされている.今回,NBI併用拡大観察で主膵管内の腫瘍形態,血管像を詳細に観察し,膵管進展評価と術前病理診断ができたIPMCの一例を経験した.
- 1 May 2013
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 77 (5) , AB366
Su1554 Evaluation of Submucosal Fibrosis Using Endoscopic Ultrasonography Prior to Colorectal Endoscopic Submucosal Dissection
- 1 May 2013
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 77 (5) , AB366
Su1554 Evaluation of Submucosal Fibrosis Using Endoscopic Ultrasonography Prior to Colorectal Endoscopic Submucosal Dissection
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Su1950 Hypertension Exacerbates Hepatic Fibrosis Induced by a Choline-Deficient L-Amino Acid-Defined Diet in Rats
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Su1950 Hypertension Exacerbates Hepatic Fibrosis Induced by a Choline-Deficient L-Amino Acid-Defined Diet in Rats
- Open Access
- 8 May 2011
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 9 (1) , 55
Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety
Hepatocyte growth factor (HGF) stimulates hepatocyte proliferation, and also acts as an anti-apoptotic factor. Therefore, HGF is a potential therapeutic agent for treatment of fatal liver diseases. We performed a translational medicine protocol with recombinant human HGF (rh-HGF), including a phase I/II study of patients with fulminant hepatitis (FH) or late-onset hepatic failure (LOHF), in order to examine the safety, pharmacokinetics, and clinical efficacy of this molecule. Potential adverse effects identified through preclinical safety tests with rh-HGF include a decrease in blood pressure (BP) and an increase in urinary excretion of albumin. Therefore, we further investigated the effect of rh-HGF on circulatory status and renal toxicity in preclinical animal studies. In a clinical trial, 20 patients with FH or LOHF were evaluated for participation in this clinical trial, and four patients were enrolled. Subjects received rh-HGF (0.6 mg/m2/day) intravenously for 12 to 14 days. We established an infusion method to avoid rapid BP reduction in miniature swine, and confirmed reversibility of renal toxicity in rats. Although administration of rh-HGF moderately decreased BP in the participating subjects, this BP reduction did not require cessation of rh-HGF or any vasopressor therapy; BP returned to resting levels after the completion of rh-HGF infusion. Repeated doses of rh-HGF did not induce renal toxicity, and severe adverse events were not observed. Two patients survived, however, there was no evidence that rh-HGF was effective for the treatment of FH or LOHF. Intravenous rh-HGF at a dose of 0.6 mg/m2 was well tolerated in patients with FH or LOHF; therefore, it is desirable to conduct further investigations to determine the efficacy of rh-HGF at an increased dose.
- 8 May 2011
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 9 (1) , 55
Open AccessSafety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety
Hepatocyte growth factor (HGF) stimulates hepatocyte proliferation, and also acts as an anti-apoptotic factor. Therefore, HGF is a potential therapeutic agent for treatment of fatal liver diseases. We performed a translational medicine protocol with recombinant human HGF (rh-HGF), including a phase I/II study of patients with fulminant hepatitis (FH) or late-onset hepatic failure (LOHF), in order to examine the safety, pharmacokinetics, and clinical efficacy of this molecule. Potential adverse effects identified through preclinical safety tests with rh-HGF include a decrease in blood pressure (BP) and an increase in urinary excretion of albumin. Therefore, we further investigated the effect of rh-HGF on circulatory status and renal toxicity in preclinical animal studies. In a clinical trial, 20 patients with FH or LOHF were evaluated for participation in this clinical trial, and four patients were enrolled. Subjects received rh-HGF (0.6 mg/m2/day) intravenously for 12 to 14 days. We established an infusion method to avoid rapid BP reduction in miniature swine, and confirmed reversibility of renal toxicity in rats. Although administration of rh-HGF moderately decreased BP in the participating subjects, this BP reduction did not require cessation of rh-HGF or any vasopressor therapy; BP returned to resting levels after the completion of rh-HGF infusion. Repeated doses of rh-HGF did not induce renal toxicity, and severe adverse events were not observed. Two patients survived, however, there was no evidence that rh-HGF was effective for the treatment of FH or LOHF. Intravenous rh-HGF at a dose of 0.6 mg/m2 was well tolerated in patients with FH or LOHF; therefore, it is desirable to conduct further investigations to determine the efficacy of rh-HGF at an increased dose.
- Open Access
- 4 May 2011
- Published by Spandidos Publications in Oncology Reports
- Vol. 26 (2) , 335-341
Hepatocyte growth factor ameliorates mucosal injuries leading to inhibition of colon cancer development in mice
Hepatocyte growth factor (HGF), which facilitates the repair of injured mucosa, has the potential to be a new therapeutic agent for inflammatory bowel disease (IBD). However, given that the incidence of colorectal cancer increases continuously with disease duration in patients with IBD, the fact that HGF is a potent mitogen for intestinal epithelial cells may further heighten the risk of bowel cancer in this patient population. In this study, we examined the effects of recombinant HGF on colorectal cancer development in mice with or without experimentally induced colitis. Although HGF stimulated proliferation of colonic epithelial cells in normal mucosa, the development of colorectal cancer induced by repeated injection of azoxymethane (AOM) was significantly inhibited by HGF treatment. In a mouse model of colitis-associated cancer, colorectal cancer frequently developed despite only a single injection of AOM prior to three cycles of dextran sulfate sodium administration. However, HGF treatment significantly facilitated the repair of injured mucosa, leading to inhibition of colorectal cancer development in a dose-dependent manner. Thus, HGF-induced repair of injured mucosa inhibits rather than accelerates the development of colorectal cancer, and these results also suggest the importance of blocking the cycles of mucosal injury and repair to prevent colitis-associated colorectal cancer.
- 4 May 2011
- Published by Spandidos Publications in Oncology Reports
- Vol. 26 (2) , 335-341
Open AccessHepatocyte growth factor ameliorates mucosal injuries leading to inhibition of colon cancer development in mice
Hepatocyte growth factor (HGF), which facilitates the repair of injured mucosa, has the potential to be a new therapeutic agent for inflammatory bowel disease (IBD). However, given that the incidence of colorectal cancer increases continuously with disease duration in patients with IBD, the fact that HGF is a potent mitogen for intestinal epithelial cells may further heighten the risk of bowel cancer in this patient population. In this study, we examined the effects of recombinant HGF on colorectal cancer development in mice with or without experimentally induced colitis. Although HGF stimulated proliferation of colonic epithelial cells in normal mucosa, the development of colorectal cancer induced by repeated injection of azoxymethane (AOM) was significantly inhibited by HGF treatment. In a mouse model of colitis-associated cancer, colorectal cancer frequently developed despite only a single injection of AOM prior to three cycles of dextran sulfate sodium administration. However, HGF treatment significantly facilitated the repair of injured mucosa, leading to inhibition of colorectal cancer development in a dose-dependent manner. Thus, HGF-induced repair of injured mucosa inhibits rather than accelerates the development of colorectal cancer, and these results also suggest the importance of blocking the cycles of mucosal injury and repair to prevent colitis-associated colorectal cancer.
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Human Neutrophil Peptides Exacerbate Experimental Colitis Through a T Cell-Independent Mechanism
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Human Neutrophil Peptides Exacerbate Experimental Colitis Through a T Cell-Independent Mechanism
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Hepatocyte Growth Factor Inhibits Colon Cancer Development in a Mouse Model of Ulcerative Colitis
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Hepatocyte Growth Factor Inhibits Colon Cancer Development in a Mouse Model of Ulcerative Colitis
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
M1825 Repeated Enemas of Recombinant Human Hepatocyte Growth Factor Ameliorate Rat Experimental Colitis Without Increasing Serum HGF Levels
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
M1825 Repeated Enemas of Recombinant Human Hepatocyte Growth Factor Ameliorate Rat Experimental Colitis Without Increasing Serum HGF Levels
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5)
W1104 Treatment Strategies for Intestinal Behcet's Disease: A Retrospective Analysis of Infliximab and Other Therapies
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5)
W1104 Treatment Strategies for Intestinal Behcet's Disease: A Retrospective Analysis of Infliximab and Other Therapies